Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion type Assertion NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_head.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion description "[In contrast, in patients carrying both ligands, KIR2DS5 was associated with reduced LFS (p=0.0056; HR 0.3; 95% CI 0.1-0.7) and higher relapse rate (p=0.02; HR 0.35, 95% CI 0.1-0.8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_provenance.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion evidence source_evidence_literature NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_provenance.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion SIO_000772 18555529 NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_provenance.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion wasDerivedFrom befree-20140225 NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_provenance.
- NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_assertion wasGeneratedBy ECO_0000203 NP698842.RA99pYfQvEIkHyRFH4O0TM30WqE73pAaGUiyUoE_xcivU130_provenance.